Efficacy assessments of SF001, a next-generation polyene antifungal, in a neutropenic mouse model of invasive fusariosis
Antimicrobial Agents and Chemotherapy · 07.05.2025 · 69 (5)
DOI: 10.1128/aac.01802-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 07.05.2025. Verfasst von Teclegiorgis Gebremariam und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, The Lundquist Institute for Biomedical Innovation at Harbor-University of California Los Angeles (UCLA) Medical Cent…. Hauptthemen laut MEDLINE: Fusariosis, Antifungal Agents, Fusarium, Polyenes. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Elion Therapeutics.
Abstract (Originalsprache)
Fusariosis has high mortality rates with limited treatment options. Owing to its rarity, comparative clinical trials are hard to perform. SF001 is a novel, next-generation polyene drug, rationally designed to reduce potential for systemic toxicity, with long-acting, potent, broad-spectrum fungicidal activity. We compared the in vitro activity and in vivo efficacy of SF001 with liposomal amphotericin B (LAMB) in treating immunosuppressed mice infected with hematogenously disseminated fusariosis. The minimum inhibitory concentration (MIC) of SF001 and LAMB against Fusarium solani or Fusarium oxysporum strains (at 100% inhibition) ranged between 0.5–8 µg/mL and 1–>16 µg/mL, respectively. In the hematogenously disseminated fusariosis model, treatment with SF001 or LAMB enhanced the median survival time vs placebo (7, 10, and 9 days at 3, 7.5, and 30 mg/kg of SF001, respectively, and 12.5 days for LAMB at 7.5 mg/kg vs 6.5 days for placebo, P < 0.0001). SF001 and LAMB treatment enhanced the overall survival by day 21 (40% and 25% for SF001 at 7.5 mg/kg and 30 mg/kg, respectively, 30% for LAMB at 7.5 mg/kg and 0% for placebo). The survival data were mirrored in the kidney and brain fungal burden results with ~2–3 log 10 reduction in conidial equivalents/gram for either treatment vs placebo. Furthermore, the reduction in tissue fungal burden was corroborated by histopathological data from target organs, showing reduced or no abscesses in SF001- or LAMB-treated mice. Our data show comparable activity of SF001 to LAMB, thereby supporting the continued development of SF001 for the treatment of invasive fusariosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, The Lundquist Institute for Biomedical Innovation at Harbor-University of California Los Angeles (UCLA) Medical Center, Torrance, California, USA.
- The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
- David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
ORCID-Profile: Nathan P Wiederhold, Ashraf S Ibrahim
Förderung
- Elion Therapeutics
Zitieren
APA
Gebremariam, T., Gu, Y., Patterson, H., Youssef, E., Alkhazraji, S., Elsayed, T., Wiederhold, N. P., & Ibrahim, A. S. (2025). Efficacy assessments of SF001, a next-generation polyene antifungal, in a neutropenic mouse model of invasive fusariosis. Antimicrobial Agents and Chemotherapy, 69(5). https://doi.org/10.1128/aac.01802-24
Vancouver
Gebremariam T, Gu Y, Patterson H, Youssef E, Alkhazraji S, Elsayed T, et al. Efficacy assessments of SF001, a next-generation polyene antifungal, in a neutropenic mouse model of invasive fusariosis. Antimicrobial Agents and Chemotherapy. 2025;69(5). doi:10.1128/aac.01802-24
BibTeX
@article{Gebremariam2025,
author = {Gebremariam, Teclegiorgis and Gu, Yiyou and Patterson, Hoja and Youssef, Eman and Alkhazraji, Sondus and Elsayed, Tasneem and Wiederhold, Nathan P and Ibrahim, Ashraf S},
title = {Efficacy assessments of SF001, a next-generation polyene antifungal, in a neutropenic mouse model of invasive fusariosis},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
volume = {69},
number = {5},
doi = {10.1128/aac.01802-24}
}
EUVIMED